28-09-2015
Photo: Courtesy of Celgene (https://www.celgene.com/media-library/celgene-logo-with-tagline-no-background/)
The US Patent and Trademark Office (USPTO) has rejected a request by biopharmaceutical company Celgene to sanction hedge fund manager Kyle Bass and his organisation the Coalition for Affordable Drugs.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Kyle Bass, Coalition for Affordable Drugs, Celgene, PTAB, inter partes reviews, IPRs, USPTO, US Patent and Trademark Office, Patent Trial and Appeal Board
